Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P860004/S459

SynchroMed Infusion System; Ascenda Intrathecal Catheters

Medtronic, Inc. · Decision date Aug 8, 2026

FDA DECISIONP860004/S459

What did the FDA decide?

FDA records P860004/S459 as a supplement to PMA P860004, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 8, 2026.

FDA approval order statement

to update acceptance criteria for printed wiring boards
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
General Hospital
Decision date
Aug 8, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P860004/S459
Regulatory pathway
PMA supplement
Product code
LKK
Decision code
OK30
Decision date
Aug 8, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Pump, infusion, implanted, programmable.

Product code
LKK
FDA device class
3

For the original device and its historical approval scope, see PMA P860004. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P860004 · Original PMA

    MEDTRONIC(R) SYNCHROMED(TM) PUMP & INFUSION SYSTEM

  2. P860004/S445 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters

  3. P860004/S446 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters

  4. P860004/S447 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters

  5. P860004/S448 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters

  6. P860004/S449 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters

  7. P860004/S450 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters (Drug Delivery Infusion Pump 8667); (Drug Delivery Infusion

  8. P860004/S452 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters

  9. P860004/S451 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters

  10. P860004/S454 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters

  11. P860004/S453 · Related supplement

    SynchroMed Infusion Systems

  12. P860004/S455 · Related supplement

    SynchroMed Infusion System; Ascenda Intrathecal Catheters

  13. P860004/S443 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters

  14. P860004/S457 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters (Drug Delivery Infusion Pump 8667)

  15. P860004/S456 · Related supplement

    Drug Delivery Infusion Pump Model 8667

  16. P860004/S459 received

    Application receipt date recorded by FDA.

  17. P860004/S459 · FDA decision

    30-Day Notice

  18. P860004/S460 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters

  19. P860004/S461 · Related supplement

    SynchroMed III Pump Drug Delivery Infusion Pump

  20. P860004/S462 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters

  21. P860004/S458 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters

  22. P860004/S464 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters TDD (Drug Delivery Infusion Pump 8667), TDD (Drug Delivery I

  23. P860004/S465 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters

Timeline entries are records held by MedtechLedger for P860004. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P860004

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA approvalMar 14, 1988FDA
Medtronic, Inc.PMA supplementJul 17, 2025FDA
Medtronic, Inc.PMA supplementJul 17, 2025FDA
Medtronic, Inc.PMA supplementAug 28, 2025FDA
Medtronic, Inc.PMA supplementAug 29, 2025FDA
Medtronic, Inc.PMA supplementSep 5, 2025FDA
Medtronic, Inc.PMA supplementSep 18, 2025FDA
Medtronic, Inc.PMA supplementOct 16, 2025FDA
Medtronic, Inc.PMA supplementNov 13, 2025FDA
Medtronic, Inc.PMA supplementNov 26, 2025FDA
Medtronic, Inc.PMA supplementDec 19, 2025FDA
Medtronic, Inc.PMA supplementDec 22, 2025FDA
Medtronic, Inc.PMA supplementJan 20, 2026FDA
Medtronic, Inc.PMA supplementFeb 6, 2026FDA
Medtronic, Inc.PMA supplementFeb 12, 2026FDA
Medtronic, Inc.PMA supplementAug 13, 2026FDA
Medtronic, Inc.PMA supplementAug 21, 2026FDA
Medtronic, Inc.PMA supplementOct 16, 2026FDA
Medtronic, Inc.PMA supplementOct 27, 2026FDA
Medtronic, Inc.PMA supplementOct 29, 2026FDA
Medtronic, Inc.PMA supplementOct 30, 2026FDA

Explore the linked device profile

Other records with product code LKK

Product / regulatory recordCompanyPathwayDecision dateSource
Intera OncologyPMA supplementMar 16, 2026FDA
Intera OncologyPMA supplementFeb 26, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
7000 Central Ave., NE, Minneapolis, MN, 55432

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records